(256 days)
Not Found
No
The device description details a lateral flow immunoassay based on antigen-antibody reactions, which is a traditional chemical detection method. There is no mention of algorithms, data processing, or any technology typically associated with AI/ML. The performance studies focus on the chemical assay's accuracy and reproducibility.
No.
The 'RapidOne' - Barbiturate Test is a diagnostic device used for the detection of barbiturates in urine, providing only a preliminary analytical test result. It is not designed to treat, prevent, or mitigate any disease or condition.
Yes
This device is a diagnostic device because its intended use is for the detection of barbiturate in human urine, which provides information for the diagnosis or monitoring of a medical condition (drug use). It screens for the presence of a specific substance in a biological sample.
No
The device description clearly outlines a physical lateral flow immunoassay strip with a membrane, reagent pad, and visible lines, indicating it is a hardware-based test.
Based on the provided information, the device "RapidOne' - Barbiturate Test" is indeed an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states it is for the detection of barbiturate in urine, which is a human biological specimen. It is used to provide a qualitative detection of secobarbital.
- Device Description: The description details an immunoassay that analyzes a sample (urine) to detect the presence of a specific substance (barbiturate) based on antigen-antibody reactions. This is a characteristic method used in IVD devices.
- Performance Studies: The document describes performance studies conducted using human urine samples to evaluate the device's ability to detect the target analyte.
- Predicate Device: The mention of a predicate device (K990107; Forefront Diagnostics, Inc. 'Instacheck' Drug Screen -Barbiturate Test) which is also a drug screening test for urine, further supports its classification as an IVD.
The definition of an IVD generally includes devices intended for use in vitro for the examination of specimens derived from the human body to provide information for diagnostic purposes. This device fits that description by analyzing urine to detect the presence of barbiturates, which can be used as preliminary information for diagnostic purposes (e.g., drug screening).
N/A
Intended Use / Indications for Use
'RapidOne' - Barbiturate Test is a one-step, lateral flow immunoassay for the detection of barbiturate in urine. 'RapidOne' - Barbiturate Test is intended for use in the qualitative detection of secobarbital in human urine at 300 ng/ml.
'RapidOne' - Barbiturate Test is intended for professional use. It is not intended for over the counter sale to non-professionals. The assay is easy to perform, but should not be used without proper supervision. This immunoassay is a simplified qualitative screening method that provides only a preliminary result for use in determining the need for additional or confirmatory testing, i.e., gas-chromatography/mass spectrometry (GC/MS).
'RapidOne' - Barbiturate Test provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a more confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Clinical and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used.
Product codes
DIS
Device Description
The assay employed in the 'RapidOne'- Barbiturate Test is based on the same principle of highly specific reaction between antigens and antibodies.
This assay is a one-step, immunoassay in which a specially labeled drug (drug conjugate) competes with drug which may be present in the sample for the limited number of binding sites on the antibody. The test device consists of a membrane strip onto which anti-amphetamine monoclonal antibody has been immobilized. A colloidal gold-BSAamphetamine complex is dried on a reagent pad. In the absence of any drug in the urine sample, the colloidal gold-complex moves with the urine by capillary action to contact the immobilized drug antibody. An antibody-antigen reaction occurs forming a visible line in the 'test' area. The formation of a visible line in the test area occurs when the test is negative.
When drug is present in the urine sample, the drug or metabolite will compete with the immobilized drug conjugate in the test area for the limited antibody sites on the colloidal gold-antibody complex. If sufficient amount of drug is present, it will fill all of the available binding sites, thus preventing attachment of the labeled antibody to the drug conjugate. An absence of a color band (line) in the test area is indicative of a positive result.
A control band (line), comprised of a different antibody/antigen reaction, is present on the membrane strip. The control line is not influenced by the presence of absence of drug in the urine, and therefore, should be present in all reactions.
A negative urine will produce two colored bands, and a positive sample will produce only one band.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
human urine
Indicated Patient Age Range
Not Found
Intended User / Care Setting
professional use
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
'RapidOne'-Barbiturate Test was compared to 'Instacheck' Drug Screen-Barbiturate Test. Ninety (90) samples were selected for evaluation, fifty (50) of which were found to be drug-free and forty (40) tested as positive by Syva EMIT-II. The forty positive specimens were confirmed and quantified by GC/MS. Both immunoassays correctly identified all of the specimens which contained no drug as negative and determined the 40 drug-containing specimens, ranging in concentration of 310 ng/ml to 10000 ng/ml, to be positive.
Revoducibility was evaluated using control urines containing concentrations above and below the stated cut-off. Negative urines were also used. Each sample, at each concentration of analyte, was tested 4 times, twice daily, for 5 days.
Key Metrics
| Conc. (ng/ml) | # | Result | Precision |
|---|---|---|---|
| 0 | 40 | 40/40 neg | >99% |
| 150 | 40 | 40/40 neg | >99% |
| 225 | 40 | 32/40 pos | >20% |
| 300 | 40 | 40/40 pos | >99% |
| 375 | 40 | 40/40 pos | >99% |
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 862.3150 Barbiturate test system.
(a)
Identification. A barbiturate test system is a device intended to measure barbiturates, a class of hypnotic and sedative drugs, in serum, urine, and gastric contents. Measurements obtained by this device are used in the diagnosis and treatment of barbiturate use or overdose and in monitoring levels of barbiturate to ensure appropriate therapy.(b)
Classification. Class II (special controls). A barbiturate test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (e.g., programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).
0
APH 3 100
510(k) Summary
| Submitter's Name/Address: | Contact Person: |
|---|---|
| American Bio Medica Corporation | |
| 300 Fairview Avenue | |
| Hudson, N.Y. 12534 | Henry Wells |
| Vice President of Product | |
| Development | |
| Phone: 518-822-8882 | |
| Fax: 518-822-0391 | |
| Date of Preparation of this Summary: | June 30, 1999 |
Device Trade of Proprietary Name:
Device Common/Usual Name or Classification Name:
'RapidOne'-Barbiturate Test
Barbiturate test system
Classification Number/Class
21 C.F.R. § 862.3150 (Class II)
This 510(k) Summary is being submitted in accordance with the requirements of 21 CFR 807.92.
The assigned 510(k) number is: K992451
Predicate Device: Forefront Diagnostics, Inc. 'Instacheck' Drug Screen -Barbiturate Test (510(k) No.K990107.)
Test Description:
The assay employed in the 'RapidOne'- Barbiturate Test is based on the same principle of highly specific reaction between antigens and antibodies.
This assay is a one-step, immunoassay in which a specially labeled drug (drug conjugate) competes with drug which may be present in the sample for the limited number of binding sites on the antibody. The test device consists of a membrane strip onto which anti-amphetamine monoclonal antibody has been immobilized. A colloidal gold-BSAamphetamine complex is dried on a reagent pad. In the absence of any drug in the urine sample, the colloidal gold-complex moves with the urine by capillary action to contact the immobilized drug antibody. An antibody-antigen reaction occurs forming a visible line in the 'test' area. The formation of a visible line in the test area occurs when the test is negative.
When drug is present in the urine sample, the drug or metabolite will compete with the immobilized drug conjugate in the test area for the limited antibody sites on the colloidal gold-antibody complex. If sufficient amount of drug is present, it will fill all of the available binding sites, thus preventing attachment of the labeled antibody to the drug
1
conjugate. An absence of a color band (line) in the test area is indicative of a positive result.
A control band (line), comprised of a different antibody/antigen reaction, is present on the membrane strip. The control line is not influenced by the presence of absence of drug in the urine, and therefore, should be present in all reactions.
A negative urine will produce two colored bands, and a positive sample will produce only one band.
IntendedUse:
'RapidOne's Barbiturate Test is used for the qualitative detection of secobarbital in human urine. This immunoassay is a simplified qualitative screening method that provides only a preliminary result for use in determining the need for additional or confirmatory testing, i.e., gas chromatography/mass spectrometry (GC/Ms).
Performance Characteristics:
'RapidOne'-Barbiturate Test will detect 300 ng/ml of secobarbital in urine.
'RapidOne'-Barbiturate Test was compared to 'Instacheck' Drug Screen-Barbiturate Test. Ninety (90) samples were selected for evaluation, fifty (50) of which were found to be drug-free and forty (40) tested as positive by Syva EMIT-II. The forty positive specimens were confirmed and quantified by GC/MS. Both immunoassays correctly identified all of the specimens which contained no drug as negative and determined the 40 drug-containing specimens, ranging in concentration of 310 ng/ml to 10000 ng/ml, to be positive.
Revoducibility was evaluated using control urines containing concentrations above and below the stated cut-off. Negative urines were also used. Each sample, at each concentration of analyte, was tested 4 times, twice daily, for 5 days.
| Conc. (ng/ml) | # | Result | Precision |
|---|---|---|---|
| 0 | 40 | 40/40 neg | >99% |
| 150 | 40 | 40/40 neg | >99% |
| 225 | 40 | 32/40 pos | >20% |
| 300 | 40 | 40/40 pos | >99% |
| 375 | 40 | 40/40 pos | >99% |
Conclusion:
'RapidOne'-Barbiturate Test is substantially equivalent to Instacheck' - Drug Screen -Barbiturate Test
2
Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" arranged around the perimeter. Inside the circle is a stylized image of an eagle with three curved lines representing its wings.
Public Health Service
APR 3 2000 Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
Henry Wells, Ph.D. Vice President of Product Development American Bio Medica Corporation 122 Smith Road Kinderhook, New York 12106
Re: K992451
Trade Name: 'RapidOne' - Barbiturate Test Regulatory Class: II Product Code: DIS Dated: February 14, 2000 Received: February 15, 2000
Dear Dr. Wells:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
3
Page 2
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device. please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR 807,97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".
Sincerely yours,
Steven Butman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
רי
510(k) Number (if known): K993451
'RapidOne' - Barbiturate Test Device Name:
Indications For Use:
'RapidOne' - Barbiturate Test is a one-step, lateral flow immunoassay for the detection of barbiturate in urine. 'RapidOne' - Barbiturate Test is intended for use in the qualitative detection of secobarbital in human urine at 300 ng/ml.
'RapidOne' - Barbiturate Test is intended for professional use. It is not intended for over the counter sale to non-professionals. The assay is easy to perform, but should not be used without proper supervision. This immunoassay is a simplified qualitative screening method that provides only a preliminary result for use in determining the need for additional or confirmatory testing, i.e., gas-chromatography/mass spectrometry (GC/MS).
'RapidOne' - Barbiturate Test provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a more confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Clinical and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used.
Dean Cooper
(Division Sign-Off)
Division of Clinical Laboratory Devices
510(k) Number K992451
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use
(Per 21 CFR 801.109)
OR
Over-The-Counter Use_